台股 » 個股 » 逸達 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

逸達

(6576)
  • 股價
    63.6
  • 漲跌
    ▼0.8
  • 漲幅
    -1.24%
  • 成交量
    145
  • 產業
    上櫃 生技醫療類股▼2.63%
  • 118人加入追蹤

    立即追蹤

  • 本地時間:13:30

     
逸達 (6576)籌碼相關-永豐金-南投 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

Created with Highstock 1.3.7Zoom券商分點個股進出嗨投資 histock.tw05/1005/2406/0806/2207/0607/2208/0208/1608/3009/1409/2810/1210/2611/0811/2212/0612/2001/0401/1802/0802/2403/0803/1803/2804/1004/2004/225060708090May '24Jul '24Sep '24Nov '24Jan '25Mar '2560d90dAll

永豐金-南投 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/04/2100.00064.9063.6002070.00%
2025/04/140.163.4000.0063.500.12080.05%
2025/04/110.263.0000.0064.400.22070.08%
2025/04/010.178.6000.0079.100.12050.04%
2025/03/26083.9000.0083.4002030.00%
2025/03/19083.9000.0083.2001980.00%
2025/03/13085.0000.0083.7002070.00%
2025/02/24085.9000.0086.0002380.00%
2025/02/13284.0000.0083.9022190.91%
2025/02/12183.5000.0083.5012170.46%
2025/01/1500.00476.1576.30-4194-2.06%
2025/01/0300.00178.0077.20-1190-0.53%
2025/01/0200.00177.5077.40-1187-0.53%
2024/12/1800.00275.6075.90-2171-1.17%
2024/12/12374.2000.0073.7031591.88%
2024/12/1100.00174.0073.80-1158-0.63%
2024/12/09175.80175.5075.4001490.00%
2024/11/29077.3000.0077.0001330.00%
2024/11/20176.5000.0076.8011010.99%
2024/11/1200.00176.3076.00-1107-0.93%
2024/11/11177.5000.0076.7011080.92%
2024/11/05076.5000.0076.6001050.01%
2024/10/09180.5000.0080.7011580.63%
2024/09/2300.00183.0082.20-1201-0.50%
2024/09/16079.8000.0080.0002470.00%
2024/09/05079.0000.0078.8002650.00%
2024/09/04278.8000.0078.9022720.73%
2024/08/14079.2000.0078.4002950.00%
2024/08/01080.4000.0080.4002900.00%
2024/07/03084.2000.0084.1002730.00%
2024/06/25083.405883.1983.50-58260-22.27%
2024/06/2400.00593.8089.20-5238-2.10%
2024/06/1700.00298.7098.70-2220-0.91%
2024/05/14093.3000.0093.8003230.00%
2024/05/09093.9200.0093.8003220.00%
2024/05/0800.00094.1094.4003200.00%
2024/05/06095.0000.0094.6003180.00%
逸達兒童中樞性早熟三期臨床 三度獲DSMB正面回饋持續進行Anue鉅亨-2025/02/17
逸達受美國經銷商指示不定期出貨 1月營收年減逾6成Anue鉅亨-2025/02/08
逸達前列腺癌新劑型新藥 確立美國藥證審查完成目標日Anue鉅亨-2025/01/14
逸達 相關文章
逸達 相關影音